News

The interim analysis showed that Sputnik V vaccine has shown an efficacy rate of 92% after the second dose in the patients. Sputnik V vaccine is based on

NAVIGATOR met the primary endpoint with tezepelumab added to standard of care (SoC) demonstrating a statistically significant and clinically meaningful1 reduction in the annualized asthma exacerbation rate (AAER) over

SCD, which is a common single-gene disorder, is estimated to affect over 70,000 in the EU-27 and up to 100,000 people in the US. The status was provided

The trial, being conducted at Hoag Hospital in Newport Beach, California, enrolled 20 volunteers across two dose levels and the subject screening for the Phase I expansion cohort

According to BlueWillow Biologics, the preclinical research shown that the company’s nasal vaccine adjuvant combined with Medigen’s S-2P spike protein enabled to significantly neutralise antibody response. The research

Following a pre-specified interim analysis, the DSMB indicated that cabotegravir met the primary objective of demonstrating superiority when compared to the current standard of care for women, daily

The EUA status enables to use bamlanivimab 700 mg to treat mild to moderate Covid-19 in adults and paediatric patients aged 12 years and older with a positive

According to Neurocritical Care Society Guidelines, status epilepticus, which is classified as a single epileptic seizure lasting more than five minutes or two or more seizures within a

The interim analysis showed that BNT162b2 vaccine candidate is over 90% effective in preventing Covid-19 in participants without evidence of prior SARS-CoV-2 infection. BioNTech co-founder and CEO Ugur